# Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)

> **NCT01635803** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 296 (estimated)

## Conditions studied

- Retinal Vein Occlusion

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01635803
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-06
- **Primary completion:** 2016-06
- **Final completion:** —
- **Target enrollment:** 296 (ESTIMATED)
- **Last updated:** 2015-07-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01635803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01635803, "Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01635803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*